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Therapeutic Improvement of a Stroma-Targeted CRAd
by Incorporating Motives Responsive to the Melanoma
Microenvironment
Diego L. Viale1,5, Eduardo G. Cafferata1, David Gould2, Cecilia Rotondaro1, Yuti Chernajovsky2,
David T. Curiel3,4, Osvaldo L. Podhajcer1 and M. Veronica Lopez1
We have previously designed a conditionally replicative oncolytic adenovirus (CRAd) named Ad-F512 that can
target both the stromal and the malignant melanoma cell compartments. The replication capacity of this CRAd is
driven by a 0.5-Kb SPARC promoter fragment (named F512). To improve CRAd’s efficacy, we cloned into F512
motives responsive to hypoxia (hypoxia-responsive element (HRE)) and inflammation (nuclear factor kappa B) to
obtain a chimeric promoter named kBF512HRE. Using luciferase as a reporter gene, we observed 10–15-fold
increased activity under hypoxia and 10–80-fold induction upon tumor necrosis factor-a addition. We next
constructed a CRAd (Ad-kBF512HRE) where E1A activity was under kBF512HRE regulation. Treatment of nude mice
harboring established tumors made of a mix of SB2 melanoma cells and WI-38 fibroblasts with Ad-kBF512HRE led
to the complete elimination of tumors in 100% of mice (8/8). Moreover, Ad-5/3-kBF512HRE, a viral variant
pseudotyped with a chimeric 5/3 fiber, exerted a strong lytic effect on CAR-negative melanoma cells and was
highly effective in vivo on established tumors made of melanoma cells and WI-38 fibroblasts, leading to the
complete elimination of 4/5 tumors. These results indicate that this improved stroma-targeted oncolytic
adenovirus can override the resistance of melanoma tumors and might become of significant importance for
melanoma therapeutics.
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INTRODUCTION
Although melanoma accounts for only 3–5% of all skin
cancers, it is responsible for approximately 75% of all deaths
from skin cancer worldwide and disproportionately targets
young individuals, especially women (Wu et al., 2003; Lens
and Dawes, 2004; Thompson et al., 2005). The standard
therapy for the metastatic disease remained decarbazine with
transient response rates ofo10%, although interleukin-2 treat-
ment seems to benefit a select group of patients, although with
significant associated toxicity (Schadendorf et al., 2009). Two
promising new agents, ipilimumab, a humanized mAb that
blocks the T-cell surface protein CTLA-4, and the inhibitor of
the BRAF gene, vermurafenib, seem to benefito20% of patients
and are limited by a relatively short duration that averages
6 months (Hodi et al., 2010; Chapman et al., 2011).
The use of oncolytic viruses for tumor targeting appears as a
potential powerful approach for the treatment of advanced
stages of cancer combined or not with radiotherapy or
chemotherapy (Garber, 2006; Alemany, 2007; Choi et al.,
2012). Direct treatment of accessible melanoma lesions with
a replicative herpes simplex virus expressing granulocyte-
macrophage colony-stimulating factor (Oncovex-GMCSF)
resulted in a 28% objective response in a phase II clinical
trial encouraging the initiation of a phase III study (Senzer
et al., 2009). Oncovex-GMCSF exhibits a strong antitumor
lytic activity and a highly attenuated neurovirulence due to a
mutation in the ICP34.5 gene (Senzer et al., 2009), although it
was not specifically designed to attack cancer cells nor the
supportive stroma. Few conditionally replicative oncolytic
adenoviruses (CRAds) whose replication is driven by tumor-
specific promoters and hence replicate mainly in the cancer
niche (Hogg et al., 2010) have also entered clinical trials with
promising therapeutic effects, although none have included
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melanoma patients yet (Dent et al., 2010). The lack of strong
and specific responsive promoters and the difficulties to
disseminate inside the tumor mass owing to the presence
of stromal barriers hampered the therapeutic efficacy of
oncolytic vectors (Cairns et al., 2006). We have recently
designed a stroma-targeted CRAd, Ad-F512, whose replication
is driven by a 0.5-kB SPARC promoter fragment named F512.
The rationale underlying this was that SPARC is expressed
in most stromal cells in close contact with the malignant
compartment (Podhajcer et al., 2008). In human melanomas,
SPARC is additionally expressed by the malignant cells
themselves, indicating that the CRAd could eventually
replicate in both cell compartments. Indeed, Ad-F512
exhibited therapeutic efficacy in vivo on human melanoma
tumors xenografted in nude mice (Lopez et al., 2009).
However, established melanomas made of a mix of human
melanoma cells and human fibroblasts were highly resistant to
viral attack (Lopez et al., 2009).
In the present study, we decided to make use of specific
characteristics of the melanoma microenvironment and
designed an improved version of Ad-F512. For this purpose,
we incorporated in the 0.5-Kb SPARC promoter motives
responsive to hypoxia and inflammation; this triple chimeric
promoter enabled viral replication in the stromal and malig-
nant cell compartment, and showed an enhanced response to
hypoxia and inflammation. This improved adenovirus also
showed enhanced in vivo capacity to eliminate resistant
melanomas made of malignant cells mixed with human
fibroblasts xenografted in nude mice.
RESULTS
Analysis of the F512-SPARC promoter motifs
Before adding genetic motives responsive to hypoxia and
inflammation, we performed a detailed study of the F512-
SPARC promoter motifs to establish whether its potency or
specificity can be improved. On the basis of in silico analysis
and previous studies (Hafner et al., 1995), we observed the
presence of two putative transcription initiator sequences
(INRs) and a downstream promoter element (DPE) in
addition to a TATA-like motif (TCTAAA). By using primer
extension analysis on RNA extracted from A375N melanoma
cells, we confirmed that SPARC mRNA transcription initiates
from both the INR1 and the INR2 sites of the endogenous
promoter at a ratio of 1: 2 (Figure 1a). Similar results were
observed in cervical cancer HeLa cells, although F512
transcriptional activity was extremely low (data not shown).
The existence of the DPE and the TATA-like elements, and the
fact that both INRs were active, led us to consider that F512
could be a functional dual promoter where the DPE element
could initiate transcription through INR1 and the TATA-like
sequence might work with INR2 (Figure 1a). We generated
seven mutated versions of F512 containing the consensus
TATA box, DPE, or the null version of both (Figure 1b) placed
upstream of luciferase. Replacing the TATA-box-like element
with a nonsense sequence (TATA-null) reduced F512 activity
to o20% of the activity of the native sequence (Figure 1b).
Interestingly, replacing the native TATA-like box sequence by
the consensus one also diminished F512 activity to 50% of the
levels of the native sequence (Figure 1b). Mutational studies
that rendered an INR2-null or DPE-null sequence led to 50%
inhibition of F512 transcriptional activity (Figure 1b). Neither a
DPE element that was mutagenized to obtain the other well-
characterized DPE sequence (DPE-mut1) (Juven-Gershon and
Kadonaga, 2010) nor an INR1-null sequence induced
significant changes in F512 activity (Figure 1b). Thus, F512
works as a dual promoter using the TATA-like and DPE
sequences to initiate transcription, although the TATA-like/
INR2 motives seem to be the predominant one in terms of
F512 transcriptional activity. As all the modifications that we
performed resulted in lower levels of F512 activity, we
decided to move forward with the wild-type version of F512.
Incorporation to F512 of genetic elements responsive to
melanoma microenvironment
We constructed different plasmids that included six (101 bp) or
twelve (202 bp) copies of the nuclear factor kappa B (NF-kB)-
responsive element obtained from the HIV long terminal
repeat sequence (Adriaansen et al. 2007; Khoury et al.,
2007) combined or not with three copies of the hypoxia-
responsive element (3 HRE) obtained from the mouse VEGF
promoter (from 889 to 939 bp) (Shima et al., 1996). Both
elements were cloned at different positions with respect to
F512, and the activity was assessed through luciferase
expression assays.
The dual chimeric promoters that included 3 HRE inside
(F512-HRE) or upstream (HRE-F512) of F512 exhibited 6- and
7-fold increased activity in A375N SPARC-positive human
melanoma cells compared with F512 under hypoxia, indicat-
ing that placement of 3 HRE inside F512 did not affect its
transcriptional activity (Figure 2a). The dual chimeric promo-
ters containing 6 (6kBF512) or 12 (12kBF512) copies of the
NF-kB-responsive element exhibited 9- and 17-fold induction,
respectively, upon tumor necrosis factor-a (TNF-a) addition,
indicating a superior activity of the latter (Figure 2b). No
TNF-a effect on cell viability was observed under these
conditions (data not shown).
Thus, we constructed a triple chimeric promoter where the
12kBRE motif was placed upstream of, and the HRE inside,
F512. This triple chimeric promoter (kBF512HRE) exhibited
21-, 7-, and 22-fold increased activity in the presence of
TNF-a, hypoxia, or TNF-aþhypoxia, respectively, compared
with the activity of F512 in normoxia (Figure 2c). Although no
additive effect was observed, the whole data indicate that the
triple chimeric promoter would be able to respond to low
oxygen tension and inflammatory conditions.
Activity of the chimeric promoter in an adenoviral context
The next step was to prepare a nonreplicative adeno-
virus where luciferase activity was driven by kBF512HRE
(Ad-kBF512HRE-Luc) (Figure 3a). Ad-kBF512HRE-Luc exhib-
ited 30–35, 10–20, and 30–35 increased fold activity in
melanoma cells in the presence of TNF-a, hypoxia, or TNF-
aþhypoxia, respectively, compared with Ad-F512 under the
same conditions (Figure 3b). It is noteworthy that the chimeric
promoter exhibited at least 60-fold increased activity in
A375N and SB2 cells compared with the activity observed
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in IIB-MEL-LES cells. Ad-kBF512HRE-Luc was also highly
active in WI-38 human fetal fibroblasts, reaching 84-, 14-,
and 55-fold increased activity in the presence of TNF-a,
hypoxia, or TNF-aþhypoxia, respectively, compared with
Ad-F512-Luc (Figure 3c). Overall, the data indicate that
kBF512HRE responded to hypoxia and inflammatory condi-
tions in an adenoviral context.
Construction of a CRAd driven by the kBF512HRE chimeric
promoter
Thus, a CRAd named Ad-kBF512HRE, whose replication is
driven by the kBF512HRE promoter, was constructed by
inserting the insulator-kBF512HRE promoter cassette into the
E1A region to regulate the expression of the E1a gene
(Figure 4a). We evaluated its replication capacity by assessing
the adenoviral genome copy number increase after 72 hours.
Ad-kBF512HRE exhibited an enhanced replication capacity
under TNF-aþ hypoxia in the two melanoma cell lines,
although its overall activity was much higher in SB2 mela-
noma cells compared with A375N cells (Figure 4b, c, and e).
The higher replication and lytic capacity of Ad-kBF512HRE in
SB2 cells compared with A375N cells was probably related to
the highest CAR levels observed in the former cells that
allowed higher infectivity by the CRAd (see Supplementary
Figure S1 online).
Ad-kBF512HRE also showed 2.5-fold enhanced replication
capacity in WI-38 fibroblast cells under TNF-aþ hypoxia,
although the overall activity was lower than the one observed
in SB2 cells (Figure 4d). Of note was the inhibitory effect
exerted by TNF-a on Ad-F512 replication in SB2 cells that was
not observed with the new CRAd carrying the chimeric
promoter (Figure 4b). This effect was not related to TNF-a
itself, as it showed no direct inhibitory activity on cell growth
(data not shown).
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Figure 1. Transcriptional activity of mutated versions of the SPARC promoter. (a) Primer extension analysis of mRNA transcribed from the endogenous SPARC
promoter region of A375N melanoma cells. The sequence and the main initiation sites are shown (see arrows). The location of each element (initiator
sequence (INR), TATA-like, and downstream promoter element (DPE)) and the relative activity of each initiation site is shown (right panel). Note that there is a T in
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different mutated versions of the F512-SPARC promoter. The bars represent mean±SD (n¼3). Data were analyzed by one-way analysis of variance.
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Ad-kBF512HRE exhibited improved antitumor activity in human
melanoma xenografts
We next evaluated Ad-kBF512HRE antitumor activity in vivo
in a mixed tumor model of SB2 melanoma cells and WI-38
fibroblasts that was described as partially resistant in vivo to
Ad-F512 activity (Lopez et al., 2009). Established tumors were
highly heterogenous in terms of hypoxic areas regardless of
whether they were made of malignant cells alone or
combined with WI-38 fibroblasts (Supplementary Figure S2a
and b online). It was also noteworthy that, in mixed tumors,
malignant cells accommodated mainly at the periphery of the
tumor mass, whereas fibroblasts were more evenly distributed
(Supplementary Figure S2c online). In initial experiments, we
observed that administration of five intratumoral doses of
11010 vp of Ad-F512 to mice bearing mixed SB2/WI-38
tumors did not improve mice survival compared with three
doses of the virus, and o40% of mice benefited from both
treatment schemes (Supplementary Figure S2d–f online). In
clear contrast, intratumoral administration of five doses of Ad-
kBF512HRE to mice bearing mixed SB2/WI-38 tumors led to
the complete elimination of tumors in 100% of mice in two
independent experiments, compared with o40% tumor elim-
ination in mice treated with Ad-F512 (Figure 5). Mostly
important, tumors did not recur even after more than 100
days of follow-up. Hexon staining confirmed viral replication
inside the tumor mass (Supplementary Figure S2g online).
Fiber exchange highlights the improved therapeutic efficacy of
the CRAd based on the chimeric promoter
In clear contrast with the results obtained with SB2 tumors,
administration of five doses of Ad-kBF512HRE to nude mice
bearing IIB-MEL-LES tumors had no effect on tumor growth
(Figure 6a). Flow-cytometer analysis demonstrated that IIB-
MEL-LES cells expressed neglectable levels of CAR receptor
while they expressed high levels of CD46, one of the receptors
of adenovirus type 3 (Supplementary Figure S1 online).
Therefore, we engineered Ad-kBF512HRE with a chimeric
5/3 fiber to redirect viral entry. This pseudotyped CRAd, Ad-5/
3-kBF512HRE, exhibited 405-, 230-, and 145-fold increased
replication capacity on IIB-MEL-LES cells in the presence of
TNF-a, hypoxia, and TNF-aþhypoxia, respectively, com-
pared with Ad-kBF512HRE under the same conditions
(Figure 6b). This increased replication was accompanied by
an enhanced lytic activity (Figure 6c). Fiber pseudotyping also
improved viral lytic capacity on WI-38 fibroblast, as these
cells expressed higher levels of CD46 than CAR
(Supplementary Figure S1 online and data not shown).
On the basis of the in vitro data, we further assessed the
in vivo efficacy of Ad-5/3-kBF512HRE on CAR-negative,
CD46-positive, IIB-MEL-LES-established melanoma xeno-
grafts. Administration of five doses of 11010 vp of Ad-5/3-
kBF512HRE on mice bearing established IIB-MEL-LES
melanomas led to the complete elimination of tumors in 2/4
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mice and a strong delay in tumor growth in one additional
mouse (Figure 6d), with a statistically significant increase in
survival rate (Figure 6d, insert).
Next, we established whether Ad-kBF512HRE retargeting
through pseudotyping with the 5/3 chimeric fiber can also
render mixed tumors made of IIB-MEL-LES cells and WI-38
fibroblasts sensitive to oncolytic attack. Treatment of mice
bearing established tumors made of IIB-MEL-LES and WI-38
cells with five doses of 11010 vp of Ad-5/3-kBF512HRE led
to the complete tumor elimination in 4/5 mice, a strong delay
in tumor growth in 1 additional mouse, and a significant
increase in the overall survival (Figure 6e). The effect of the
non-pseudotyped CRAd did not differ significantly from
phosphate-buffered saline (PBS) (Figure 6d and e).
DISCUSSION
Here we show that incorporation of motives responsive to
hypoxia and inflammation to a stroma-targeted conditionally
replicative adenovirus greatly improved the therapeutic
efficacy of the virus, leading to the elimination of human
melanomas established in nude mice. Virus retargeting
following engineering of a chimeric 5/3 adenovirus serotype
fiber to target melanoma tumors devoid of CAR expression
confirmed the increased potency of this improved oncolytic
adenovirus.
To enhance viral replication, we first accomplished a deep
study of the F512-SPARC promoter fragment. Mutational
analysis demonstrated that both the TATA-like and the DPE
sequences were active and that the native sequences of
both motifs exhibited better activity than the consensus one.
Thus, the F512-SPARC promoter is, to our knowledge, the first
native promoter in which both the TATA and the DPE
sequences are transcriptionally active, suggesting that F512
is a mixed-mode promoter (Juven-Gershon and Kadonaga,
2010). Further efforts to establish whether these alternate
initiation sites could be associated with specific cell types
did not succeed. Thus, the possibility that F512 will be active
in different cell types depending on the availability of the
TATA-like or the DPE-related transcription factors warrants
further investigation.
Further to the molecular analysis of the F512 promoter, we
incorporated motives responsive to hypoxia and inflammation
that are hallmarks of more aggressive melanomas and have
been shown to correlate with bad prognosis (Bedogni
and Powell, 2009). Few reports described the incorporation
of genetic responsive elements to promoters for enhanced
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transcriptional regulation of therapeutic genes (Yew et al.,
2001; Greco et al., 2002; Lee et al., 2002; Liu et al., 2004; Lee
et al., 2006; Guo et al., 2007; Poulsen et al., 2008), but only
one study attempted to combine NF-kB and HRE elements in
a plasmid that conferred only a slight enhanced activity to the
KDR promoter when assessed in primary murine endothelial
cells (Modlich et al., 2000). Here we observed that both in a
plasmid and in an adenoviral context the triple chimeric
promoter increased its transcriptional activity greatly, leading
to enhanced viral efficacy under hypoxia and upon TNF-a
addition in human melanoma cells and fetal fibroblasts.
Moreover, the oncolytic virus carrying this triple chimeric
promoter showed enhanced in vivo therapeutic efficacy both
on tumors made of melanoma cells alone and on tumors made
of a mix of melanoma cells and stromal cells. Although we
were unable to observe an in vitro synergistic effect when the
replication/lytic capacity of Ad-kBF512HRE was assessed in
the presence of hypoxiaþTNF-a, we can envisage an in vivo
positive loop because hypoxia has been shown to enhance
transient changes in NF-kB levels (Vaupel, 2010).
Pseudotyping this virus with a chimeric fiber 5/3 overrides
the natural resistance of a melanoma cell line devoid of CAR
receptors such as IIB-MEL-LES. This is consistent with previous
studies showing that some human fresh melanoma might not
express CAR (Rivera et al., 2004). Thus, assessment of viral
receptor expression in fresh melanoma samples before
treatment can help predict viral success in a potential
clinical trial.
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Figure 6. In vivo therapeutic efficacy of Ad-5/3-kBF512HRE on CAR-negative tumors. In vivo growth of subcutaneous tumors made of CAR-negative IIB-MEL-LES
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The tumor microenvironment involves the malignant cells
themselves, fibroblasts, endothelial cells, and inflammatory
cells. This microenvironment is characterized by low levels of
oxygen tension and increased proinflammatory conditions that
might enhance NF-kB responsiveness (Melnikova and Bar-Eli,
2009). New blood vessel formation by endothelial cells
and enhanced remodeling of the extracellular matrix by
neighboring fibroblasts to create either new tracks or barriers
help tumors develop beyond an initial avascular growth and
protect malignant cells from the attack of therapeutic drugs.
Moreover, the dynamic cross-talk between malignant mela-
noma cells and surrounding stromal cells is a key event for
allowing dissemination (van Kempen et al., 2008). Melanoma
and inflammatory cells induce fibroblast proliferation through
the release of platelet-derived growth factor, basic fibroblast
growth factor, and transforming growth factor-b, whereas
fibroblasts produce a series of growth factors such as IGF1,
hepatocyte growth factor, basic fibroblast growth factor, and
transforming growth factor-b that can support melanoma cell
proliferation (Hsu et al., 2002; Hendrix et al., 2003).
Recent studies have shown encouraging studies looking at
combining the oncolytic adenovirus H101 with an small
interfering RNA against Bcl2 in different human uveal mela-
noma cells lines (Huang et al., 2012). A couple of studies have
also shown that a CRAd carrying IL-24 helped in inducing
apoptosis of melanoma cells following radiotherapy (Chai
et al., 2012; Jiang et al., 2012). Thus, the possibility of acting
on human melanoma tumors with an oncolytic virus that can
target both the stromal and the malignant compartment,
respond to melanoma microenvironment, and whose
infectivity can be tailored according to cell surface
expression of viral receptors can be of significant importance
for melanoma therapeutics.
MATERIALS AND METHODS
Cell lines
See Supplementary Material online.
Plasmids and recombinant adenoviruses
See Supplementary Material online.
Primer extension
A measure of 1mg of poly(A) RNA extracted from A375N melanoma
cell line using PolyATtract mRNA Isolation System (Promega, Madi-
son, WI, USA) was annealed with 1 pmol of [g-32P] end-labeled
reverse primer (50-TCTCCAGCGGTTCCATCTTCCAGC-30). The
reverse transcripts were generated according to the protocol of Primer
Extension System-AMV Reverse Transcriptase (Promega), using 55 1C
as annealing temperature for primer and RNA binding. The same
primer was used for sequencing with fmol DNA Cycle Sequencing
System (Promega) according to the supplier’s protocol using 55 1C as
melting temperature. The extension products from primer extension
and sequencing were analyzed by 8 M urea–6% polyacrylamide gel
electrophoresis. The products were detected by gel drying and expo-
sure to phosphorimaging screens (Molecular Dynamics, Madison, WI)
for quantitative analysis using a Storm scanner and ImageQuant
software (Storm 860 by Molecular Dynamics, now GE Healthcare,
Madison, WI).
Luciferase assays and E4 real-time PCR
See Supplementary Material online.
Flow cytometry
Cells at 80% confluence were washed with PBS, detached with 5 mM
EDTA, resuspended in DMEM/F12 containing 10% fetal bovine serum
(FBS), washed again with PBS, and resuspended at a concentration of
5 106 per ml in cold PBS containing 10% FBS and 1% sodium azide
(PBS/FBS/NaAz). For further details see Supplementary Material
online.
In vitro and in vivo assays and ethics statement
All experiments were approved by the Institutional Animal Care and
Use Committee of the Fundacio´n Instituto Leloir (Protocol no. 30OP).
The Fundacio´n Instituto Leloir has an approved Animal Welfare
Assurance as a foreign institution with the Office of Laboratory
Animal Welfare, Number A5168-01.
Six- to eight-week old male athymic N:NIH (S)-nu mice (obtained
from the animal facility of the Faculty of Veterinary, University of La
Plata) were subcutaneously injected on the left flank with 5 106
melanoma cells mixed or not with 2 106 WI-38 fibroblasts. When
the average tumor volume reached 100 mm3, mice received
1 1010 vp/mouse of CRAd or vehicle (PBS) administered intratumo-
rally on days 1, 3, and 7 (three doses) or 1, 3, 5, 7, and 9 (five doses).
Sequential doses were administered in different areas of the tumor,
trying to avoid leakage. Tumor size was estimated once a week with
caliper measurements (volume¼ 0.52 (width)2 length). Mice were
followed up and then killed when tumors reached approximately
2 cm3; in several cases, data are presented as tumor growth of
individual mice, whereas in other cases, data are presented as
average tumor volume. All animals under study received food and
water ad libitum. Survival rates were calculated with the Kaplan–
Meier method, and multiple comparisons of survival were evaluated
by the Bonferroni-corrected method. A P-value 0.05/K (where K¼
number of comparisons) was considered statistically significant. Data
analysis was performed with the GraphPad Prism 5.0 software
(GraphPad Software, San Diego, CA).
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